ST Renfu announced that its holding subsidiary Yichang Renfu RFUS-188 injection recently entered a phase II clinical trial study for the treatment of acute pain. Recently, Yichang's fumidazolam injection obtained marketing approval from the UK Medicines and Health Products Administration.

ST Renfu announced that its holding subsidiary Yichang Renfu RFUS-188 injection recently entered a phase II clinical trial study for the treatment of acute pain. Recently, Yichang's fumidazolam injection obtained marketing approval from the UK Medicines and Health Products Administration.